Momentum Stock Watch: Esperion Therapeutics Inc. (ESPR)

Company Profile:

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Recent News:

Esperion Therapeutics (ESPR) announced that they have entered into a licensing agreement with Daiichi Sankyo Europe (DSE) providing DSE with exclusive rights to commercialize bempedoic acid and the bempedoic acid / ezetimibe combination pill in the European Economic Area and Switzerland.

On Nov. 10, 2018, the company announced that the final Phase 3 results from Study 3 (1002-046, also known as CLEAR Serenity) were presented at the American Heart Association (AHA) Scientific Sessions in Chicago.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

ESPR’s strengths can be seen in its strong growth compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in MACD and Stochastic oscillator and the RSI stands at 47.12 with positive bias. We rate Esperion Therapeutics Inc. (ESPR) a STRONG BUY.

About the Author

has written 10955 stories on this site.

Copyright © 2012 Nine Stocks